Portola Pharmaceuticals (PTLA) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Portola Pharmaceuticals (NASDAQ: PTLA):

  • 1/4/2018 – Portola Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. “
  • 1/2/2018 – Portola Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc..
  • 1/1/2018 – Portola Pharmaceuticals had its “buy” rating reaffirmed by analysts at William Blair.
  • 12/28/2017 – Portola Pharmaceuticals was given a new $80.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 12/28/2017 – Portola Pharmaceuticals had its “buy” rating reaffirmed by analysts at Citigroup Inc. They now have a $74.00 price target on the stock.
  • 12/21/2017 – Portola Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 12/19/2017 – Portola Pharmaceuticals was given a new $80.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 12/13/2017 – Portola Pharmaceuticals was given a new $80.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 12/7/2017 – Portola Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 12/1/2017 – Portola Pharmaceuticals is now covered by analysts at Goldman Sachs Group Inc. They set a “buy” rating and a $75.00 price target on the stock.
  • 11/7/2017 – Portola Pharmaceuticals had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $80.00 price target on the stock.

Shares of Portola Pharmaceuticals Inc (PTLA) traded up $0.65 during midday trading on Thursday, reaching $49.41. The company’s stock had a trading volume of 1,002,500 shares, compared to its average volume of 1,409,400. The company has a current ratio of 8.31, a quick ratio of 8.31 and a debt-to-equity ratio of 0.24. The company has a market cap of $3,220.00, a price-to-earnings ratio of -11.44 and a beta of 1.21. Portola Pharmaceuticals Inc has a 1-year low of $22.71 and a 1-year high of $67.10.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.49) by $0.08. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The business had revenue of $3.83 million during the quarter, compared to analyst estimates of $4.71 million. During the same period in the previous year, the company posted ($1.64) EPS. Portola Pharmaceuticals’s revenue was down 58.9% on a year-over-year basis. equities research analysts anticipate that Portola Pharmaceuticals Inc will post -4.94 earnings per share for the current year.

In other news, Director Henry Ward Wolff sold 12,000 shares of Portola Pharmaceuticals stock in a transaction on Friday, December 15th. The stock was sold at an average price of $47.00, for a total value of $564,000.00. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 5.50% of the company’s stock.

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Receive News & Ratings for Portola Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply